An AAV Gene Therapy Trial of AFTX-201 in Adults With BAG3-Associated Dilated Cardiomyopathy (DCM)

Recruiting

Phase 1

Phase 2

AFTX-201An AAV Gene Therapy Trial of AFTX-201 in Adults With BAG3-Associated Dilated Cardiomyopathy (DCM)

Sponsor:

Affinia Therapeutics

Code:

NCT07426419

Conditions

Dilated Cardiomyopathy (DCM)

BAG3 Mutation Associated Dilated Cardiomyopathy

Eligibility Criteria

Sex: All

Age: 18 - 55

Healthy Volunteers: Not accepted

Interventions

AFTX-201

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-07-27. This information was provided to ClinicalTrials.gov by Affinia Therapeutics on 2026-07-09.